IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference
IRulya Therapeutics announced senior management will participate in a fireside chat at the Craig-Hallum Biotech Catalyst Conference on October 22, 2026. The company's pipeline centers on LAM-001, with ongoing Phase 2b studies in PH-ILD and Phase 2 in BOS, and a Phase 2 SAPH trial expected to begin in Q4 2026.
Key figures
- Cash runway
- through the end of 2028
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.